MENU
+Compare
BIIB
Stock ticker: NASDAQ
AS OF
Aug 18, 12:50 PM (EDT)
Price
$137.97
Change
-$0.63 (-0.45%)
Capitalization
20.32B

BIIB Biogen Forecast, Technical & Fundamental Analysis

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan... Show more

Industry: #Biotechnology
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BIIB with price predictions
Aug 15, 2025

BIIB in downward trend: price may decline as a result of having broken its higher Bollinger Band on August 15, 2025

BIIB broke above its upper Bollinger Band on August 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In of the 36 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on BIIB as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on August 13, 2025. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

BIIB moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BIIB crossed bullishly above the 50-day moving average on August 13, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.152) is normal, around the industry mean (9.409). P/E Ratio (13.263) is within average values for comparable stocks, (23.546). BIIB's Projected Growth (PEG Ratio) (4.705) is slightly higher than the industry average of (1.848). BIIB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (2.028) is also within normal values, averaging (3.361).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

View a ticker or compare two or three
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BIIB is expected to report earnings to fall 29.80% to $3.84 per share on October 22

Biogen BIIB Stock Earnings Reports
Q3'25
Est.
$3.84
Q2'25
Beat
by $1.48
Q1'25
Beat
by $0.06
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.31
The last earnings report on July 31 showed earnings per share of $5.47, beating the estimate of $3.99. With 220.45K shares outstanding, the current market capitalization sits at 20.32B.
A.I. Advisor
published General Information

General Information

a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Binney Street
Phone
+1 617 679-2000
Employees
7570
Web
https://www.biogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PFFA21.760.01
+0.05%
Virtus InfraCap US Preferred Stock ETF
LDRI25.50N/A
N/A
iShares iBonds 1-5 Year TIPS Ladder ETF
ISEP31.53N/A
N/A
Innovator Intl Dev Pwr Bffr ETF - Sept
DDEC42.80-0.09
-0.21%
FT Vest US Equity Dp Bfr ETF Dec
NDIV27.99-0.25
-0.87%
Amplify Natural Resources Div Inc ETF

BIIB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
+2.71%
PFE - BIIB
56%
Loosely correlated
+0.12%
MRK - BIIB
48%
Loosely correlated
+1.75%
AMGN - BIIB
47%
Loosely correlated
+2.13%
NVS - BIIB
46%
Loosely correlated
+1.74%
GSK - BIIB
45%
Loosely correlated
+1.44%
More